Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae

作者：Cojutti Piergiorgio; Sartor Assunta; Righi Elda; Scarparo Claudio; Bassetti Matteo; Pea Federico^*

来源：Antimicrobial Agents and Chemotherapy, 2017, 61(10): e00794-17.

DOI：10.1128/AAC.00794-17

• meropenem
• continuous infusion
• PK/PD
• KPC-producing Klebsiella pneumoniae
• K. pneumoniae
• KPC

We assessed the population pharmacokinetics of high-dose continuous infusion (HDCI) meropenem in a cohort of patients with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae (KPC-Kp) infections. Monte Carlo simulations were used to define the permissible HDCI meropenem regimens that could be safely considered for the treatment of KPC-Kp infections due to meropenemresistant strains. Permissible doses were arbitrarily defined as those associated with a <= 10% to 15% likelihood of meropenem steady-state concentrations (C-ss) of >100 mg/liter. Probabilities of target attainment (PTA) of four incremental pharmacodynamic determinants for meropenem efficacy (100% T>(1xMIC), 100% T>(2xMIC), 100% T->3xMIC, and 100% T->4xMIC, where "T->MIC" represents the time during which the plasma concentration of this time-dependent antibacterial agent is maintained above the MIC for the pathogen) in relation to different classes of renal function were calculated. The cumulative fractions of response (CFR) for the permissible HDCI meropenem regimens were calculated against the MIC distribution of the KPC-Kp clinical isolates that were collected routinely at our University Hospital between 2013 and 2016 (n 169). Ninety-seven meropenem C-ss were included in the analysis. The final model included creatinine clearance (CrCL) as a covariate and explained 94% of the population variability. Monte Carlo simulations based on licensed dosages of up to 6 g/day predicted an acceptable PTA (>80%) of 100% T>(1xMIC) against KPC-Kp with a meropenem MIC of <= 32 mg/liter in patients with a CrCL level of <130 ml/min. Dosages of 8 g/day were needed for achieving the same target in patients with CrCL at levels of 130 to 200 ml/min. In dealing with pathogens with a meropenem MIC of 64 mg/liter, HDCI regimens using meropenem at higher than licensed levels should be considered. In these cases, real-time therapeutic drug monitoring could be a useful adjunct for optimized care. The predicted CFR were >75% in all of the classes of renal function.

• 出版日期2017-10